With high enrollment targets and a fast-moving timeline, Olema needed more than awareness for its Phase III trial, OPERA-01. They needed belief to drive rapid enrollment. Positioned to transform treatment for ER-positive, HER2-negative breast cancer, Olema partnered with AW to create a trial brand that would cut through the noise, build trust, and reflect their innovative, patient-first mission.